Therapy with biphasic insulin aspart 30/70 (NovoMix 30) improves glycemic control in patients with type 2 diabetes mellitus: resultsfrom a Russian cohort of IMPROVE observational program designed to study safety and efficiency of biphasic insulin aspart 30 inroutine clinical practice
Aim. To assess efficiency and safety of therapy at the onset and after intensification of the treatment with biphasic insulin aspart 30/70 (NovoMix 30)in patients with type 2 diabetes who failed to reach the desired level of glycemic control by using other forms of insulin. Materials and methods....
Guardado en:
Autores principales: | Marina Vladimirovna Shestakova, Akil Ballan |
---|---|
Formato: | article |
Lenguaje: | EN RU |
Publicado: |
Endocrinology Research Centre
2010
|
Materias: | |
Acceso en línea: | https://doaj.org/article/8646b5500862485d859147d6c9193c45 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
IMPROVE observational program: safety and effectiveness of biphasic insulin aspart 30 in routine clinical practice. Overview of starting characteristics of the Russian patient cohort
por: Marina Vladimirovna Shestakova, et al.
Publicado: (2009) -
Insulin therapy and body weight: benefits of biphasic human insulin analogue NovoMix 30
por: Elena Viktorovna Surkova
Publicado: (2013) -
Biphasic insulin aspart 30/70 (BIAsp 30) in the treatment of type 1 and type 2 diabetes
por: Paul Valensi
Publicado: (2009) -
Dvukhfaznyy insulin aspart 30 plyusmetformin: effektivnaya kombinatsiyadlya lecheniya sakharnogo diabeta 2 tipa
por: M Kvapil, et al.
Publicado: (2006) -
Insulin degludec/insulin aspart is the first co-formulation of basal and prandial insulin analogues
por: Ivan Ivanovich Dedov, et al.
Publicado: (2014)